Thiola - Mission Pharmacal Company

THIOLA is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of
cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria,
who are not responsive to these measures alone.

2.1 Recommended Dosage

Adults: The recommended initial dosage in adult patients is 800 mg/day. In clinical studies, the average
dosage was about 1,000 mg/day.

Pediatrics: The recommended initial dosage in pediatric patients weighing 20 kg and greater is 15 mg/kg/day.
Avoid dosages greater than 50 mg/kg per day in pediatric patients [see Warnings and Precautions (5.1), Use in
Specific Populations (8.4)].

Administer THIOLA in 3 divided doses at the same times each day at least one hour before or 2 hours after
meals.

Consider starting THIOLA at a lower dosage in patients with history of severe toxicity to d-penicillamine.

2.2 Monitoring
Measure urinary cystine 1 month after starting THIOLA and every 3 months thereafter. Adjust THIOLA dosage
to maintain urinary cystine concentration less than 250 mg/L.

Assess for proteinuria before treatment and every 3 to 6 months during treatment [see Warnings and
Precautions (5.1)].

Discontinue THIOLA in patients who develop proteinuria, and monitor urinary protein and renal function.
Consider restarting THIOLA treatment at a lower dosage after resolution of proteinuria.

Tablets for oral use:
100 mg tablets: round, white and imprinted in red with “M” on one side

THIOLA is contraindicated in patients with hypersensitivity to tiopronin or any other components of THIOLA
[see Warnings and Precautions (5.2)].

5.1 Proteinuria
Proteinuria, including nephrotic syndrome, and membranous nephropathy, have been reported with tiopronin
use. Pediatric patients receiving greater than 50 mg/kg of tiopronin per day may be at increased risk for
proteinuria [see Dosage and Administration (2.2), Adverse Reactions (6.1, 6.2), Use in Specific Populations
(8.4)]. Monitor patients for the development of proteinuria and discontinue therapy in patients who develop
proteinuria [see Dosage and Administration (2.2)].

5.2 Hypersensitivity Reactions
Hypersensitivity reactions (drug fever, rash, fever, arthralgia and lymphadenopathy) have been reported [see
Contraindications (4)].

The following adverse reactions are discussed in greater detail in other sections of the labeling:
• Proteinuria [see Warnings and Precautions (5.1)]
• Hypersensitivity [see Warnings and Precautions (5.2)]

6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in
the clinical trials of the drug cannot be directly compared to rates in the clinical trials of another drug and may
not reflect the rates observed in practice.

Adverse reactions occurring at an incidence of ≥5% in an uncontrolled trial in 66 patients with cystinuria
age 9 to 68 years are shown in the table below. Patients in group 1 had previously been treated with
d-penicillamine; those in group 2 had not. Of those patients who had stopped taking d-penicillamine due to
toxicity (34 out of 49 patients in group 1), 22 were able to continue treatment with THIOLA. In those without
prior history of d-penicillamine treatment, 6% developed reactions of sufficient severity to require THIOLA
withdrawal.
Table 1 presents adverse reactions ≥5% in either treatment group occurring in this trial.

Picture

Taste Disturbance
A reduction in taste perception may develop. It is believed to be the result of chelation of trace metals by
tiopronin. Hypogeusia is often self-limited.

6.2 Postmarketing Experience
Adverse reactions have been reported from the literature, as well as during post-approval use of THIOLA.
Because the post-approval reactions are reported voluntarily from a population of uncertain size, it is not
always possible to reliably estimate their frequency or establish a causal relationship to THIOLA exposure.
Adverse reactions reported during the postmarketing use of THIOLA are listed by body system in Table 2.

6 ADVERSE REACTIONS 6.1 Clinical Trials Experience 6.2 Postmarketing Experience

8.1 Pregnancy
Risk Summary
Available published case report data with tiopronin have not identified a drug-associated risk for major birth
defects, miscarriage, or adverse maternal or fetal outcomes. Renal stones in pregnancy may result in adverse
pregnancy outcomes (see Clinical Considerations). In animal reproduction studies, there were no adverse
developmental outcomes with oral administration of tiopronin to pregnant mice and rats during organogenesis
at doses up to 2 times a 2 grams/day human dose (based on mg/m ²). The estimated background risk of major
birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background
risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background
risk of major birth defects and miscarriage in clinically recognized pregnancies are 2% to 4% and 15% to
20%, respectively.
Clinical Considerations
Disease-associated maternal and/or embryo/fetal risk
Renal stones in pregnancy may increase the risk of adverse pregnancy outcomes, such as preterm birth and
low birth weight.
Data
Animal Data
No findings of fetal malformations could be attributed to the drug in reproduction studies in mice and rats at
doses up to 2 times the highest recommended human dose of 2 grams/day (based on mg/m ²).
8.2 Lactation
Risk Summary
There are no data on the presence of tiopronin in either human or animal milk or on the effects of the
breastfed child. A published study suggests that tiopronin may suppress milk production. Because of the
potential for serious adverse reactions, including nephrotic syndrome, advise patients that breastfeeding is not
recommended during treatment with THIOLA.
8.4 Pediatric Use
THIOLA is indicated in pediatric patients weighing 20 kg or more with severe homozygous cystinuria, in
combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation
who are not responsive to these measures alone. This indication is based on safety and efficacy data from a
trial in patients 9 years to 68 years of age and clinical experience. Proteinuria, including nephrotic syndrome,
has been reported in pediatric patients. Pediatric patients receiving greater than 50 mg/kg tiopronin per day
may be at greater risk [see Dosage and Administration (2.1, 2.2), Warnings and Precautions (5.1) and Adverse
Reactions (6.1)].
THIOLA tablets are not approved for use in pediatric patients weighing less than 20 kg or in pediatric patients
unable to swallow tablets [see Recommended Dosage (2.1)].
8.5 Geriatric Use
This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug
may be greater in patients with impaired renal function. Because elderly patients are more likely to have
decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal
function.

There is no information on overdosage with tiopronin.

THIOLA (tiopronin) immediate-release tablets are a reducing and cystine-binding thiol drug (CBTD) for oral
use. Tiopronin is N-(2-Mercaptopropionyl) glycine and has the following structure:

tiopronin-struct

Tiopronin has the empirical formula C ₅H ₉NO ₃S and a molecular weight of 163.20. In this drug product tiopronin
exists as a dl racemic mixture.

Tiopronin is a white crystalline powder, which is freely soluble in water.
Each THIOLA tablet contains 100 mg of tiopronin. The inactive ingredients in THIOLA tablets include calcium
carbonate, carnauba wax, ethyl cellulose, dimethylaminoethyl methacrylate: butyl methacrylate: methyl
methacrylate copolymer (Eudragit E 100), hydroxy-propyl cellulose, lactose monohydrate, magnesium
stearate, povidone, sugar, talc, titanium dioxide.

12.1 Mechanism of Action

The goal of therapy is to reduce urinary cystine concentration below its solubility limit. Tiopronin is an active
reducing agent which undergoes thiol-disulfide exchange with cystine to form a mixed disulfide of tiopronincysteine.
From this reaction, a water-soluble mixed disulfide is formed and the amount of sparingly soluble
cystine is reduced.
12.2 Pharmacodynamics
The decrement in urinary cystine produced by tiopronin is generally proportional to the dose. A reduction in
urinary cystine of 250-350 mg/day at tiopronin dosage of 1 g/day, and a decline of approximately 500 mg/day
at a dosage of 2 g/day, might be expected. Tiopronin has a rapid onset and offset of action, showing a fall in
cystine excretion on the first day of administration and a rise on the first day of drug withdrawal.
12.3 Pharmacokinetics
Absorption
THIOLA Tablets
When THIOLA single doses were given to fasted healthy subjects (n = 39), the median time to peak plasma
level (T _max) was 1 (range: 0.5 to 2.1) hours.
Elimination

Excretion
When tiopronin is given orally, up to 48% of dose appears in urine during the first 4 hours and up to 78% by
72 hours.

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenesis
Long-term carcinogenicity studies in animals have not been performed.
Mutagenesis
Tiopronin was not genotoxic in the chromosomal aberration, sister chromatid exchange, and in vivo
micronucleus assays.
Impairment of Fertility
High doses of tiopronin in experimental animals have been shown to interfere with maintenance of pregnancy
and viability of the fetus. In 2 published male fertility studies in rats, tiopronin at 20 mg/kg/day intramuscular
(IM) for 60 days induced reductions in testis, epididymis, vas deferens, and accessory sex glands weights and
in the count and motility of cauda epididymal sperm.

100 mg round, white, immediate-release tablet imprinted in red with “M” on one side and blank on the other
side: Bottles of 100 NDC 0178-0900-01.
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].

Lactation

Advise women that breastfeeding is not recommended during treatment with THIOLA [see Use in Specific
Populations (8.2)].

Label

Manufactured and packaged by Mission Pharmacal Company, San Antonio, TX 78230 1355
Distributed by Travere Therapeutics, Inc., San Diego, CA 92130
Copyright © 2024 Mission Pharmacal Company. All rights reserved.
L090201R0824
THL_T13758R0824

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL